The math is brutal and straightforward. A branded drug generating $800 million annually can lose 80 to 90 percent of […]

The Calendar Is Your Competitive Weapon Every pharmaceutical company has a patent expiry problem. Not because patents expire — that

The Hierarchy Problem in Pharmaceutical IP Every pharmaceutical patent portfolio has a hierarchy, whether the company managing it acknowledges one

The IPO Trap That Costs Investors Billions Biotech IPOs are uniquely dangerous investments, and not for the reasons most investors

The Model That Cost $2 Billion In the spring of 2018, a major integrated health system’s pharmacy benefit function projected

The $2.6 Billion Mistake Nobody Talks About In 2019, a mid-sized generic pharmaceutical company committed $340 million to develop a

When AbbVie filed its 132nd patent on adalimumab, the drug that became Humira, the company was not protecting a new

How executives, investors, and analysts use patent cliff intelligence to protect revenue, time acquisitions, and build portfolios that don’t collapse

Patent expiration is the most predictable crisis in pharmaceuticals. The dates are public, the revenue cliffs are calculable, and yet